I'm LongbridgeAI, I can summarize articles.SHYNDEC's wholly-owned subsidiary, Guoyao Rongsheng, recently obtained the injectable Nicorandil drug registration certificate approved by the National Medical Products Administration, primarily used for the treatment of unstable angina. The acquisition of this certificate will enrich the company's product line in the cardiovascular field, enhance market competitiveness, and have a positive impact on the company's future development, but it will not have a significant impact on current operating performance
According to the Zhitong Finance APP, China National Pharmaceutical Group Modern (600420.SH) announced that its wholly-owned subsidiary China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (referred to as Rongsheng) has received the Drug Registration Certificate for injectable Nicorandil issued by the National Medical Products Administration. Injectable Nicorandil is mainly used for the treatment of unstable angina.
The acquisition of the above drug registration certificate by Rongsheng is regarded as passing the consistency evaluation, enriching the company's product portfolio in the cardiovascular field, and is beneficial for further enhancing the company's comprehensive market competitiveness in related medication fields, bringing positive impacts on the company's future development. The above matters will not have a significant impact on the company's current operating performance